Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioTelemetry stock | 48.3

Own BioTelemetry stock in just a few minutes.

Posted

Fact checked

BioTelemetry, Inc is a diagnostics & research business based in the US. BioTelemetry shares (BEAT) are listed on the NASDAQ and all prices are listed in US Dollars. BioTelemetry employs 1,700 staff and has a trailing 12-month revenue of around USD$414.8 million.

How to buy shares in BioTelemetry

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for BioTelemetry. Find the stock by name or ticker symbol: BEAT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioTelemetry reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$48.3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioTelemetry, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of BioTelemetry. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted BioTelemetry's share price?

Since the stock market crash in March caused by coronavirus, BioTelemetry's share price has had significant negative movement.

Its last market close was USD$48.3, which is 7.35% down on its pre-crash value of USD$52.13 and 76.60% up on the lowest point reached during the March crash when the shares fell as low as USD$27.35.

If you had bought USD$1,000 worth of BioTelemetry shares at the start of February 2020, those shares would have been worth USD$614.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$977.11.

BioTelemetry share price

Use our graph to track the performance of BEAT stocks over time.

BioTelemetry shares at a glance

Information last updated 2020-12-01.
Latest market close USD$48.3
52-week range USD$27.35 - USD$56
50-day moving average USD$45.9603
200-day moving average USD$44.0565
Wall St. target price USD$54.83
PE ratio 115.4375
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.48

Buy BioTelemetry shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioTelemetry stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioTelemetry price performance over time

Historical closes compared with the close of $48.3 from 2020-11-16

1 week (2020-11-23) -7.91%
1 month (2020-10-30) 13.43%
3 months (2020-08-28) 21.08%
6 months (2020-05-29) 2.37%
1 year (2019-11-29) 4.30%
2 years (2018-11-30) -31.91%
3 years (2017-11-30) 66.55%
5 years (2015-11-30) 283.03%

Is BioTelemetry under- or over-valued?

Valuing BioTelemetry stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioTelemetry's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioTelemetry's P/E ratio

BioTelemetry's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 115x. In other words, BioTelemetry shares trade at around 115x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

BioTelemetry's PEG ratio

BioTelemetry's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.48. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioTelemetry's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioTelemetry's EBITDA

BioTelemetry's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$98.6 million.

The EBITDA is a measure of a BioTelemetry's overall financial performance and is widely used to measure a its profitability.

BioTelemetry financials

Revenue TTM USD$414.8 million
Operating margin TTM 12.84%
Gross profit TTM USD$252.5 million
Return on assets TTM 4.71%
Return on equity TTM 4.67%
Profit margin 4.26%
Book value $11.57
Market capitalisation USD$1.9 billion

TTM: trailing 12 months

Shorting BioTelemetry shares

There are currently 3.6 million BioTelemetry shares held short by investors – that's known as BioTelemetry's "short interest". This figure is 7.8% down from 3.9 million last month.

There are a few different ways that this level of interest in shorting BioTelemetry shares can be evaluated.

BioTelemetry's "short interest ratio" (SIR)

BioTelemetry's "short interest ratio" (SIR) is the quantity of BioTelemetry shares currently shorted divided by the average quantity of BioTelemetry shares traded daily (recently around 268204.75830816). BioTelemetry's SIR currently stands at 13.24. In other words for every 100,000 BioTelemetry shares traded daily on the market, roughly 13240 shares are currently held short.

However BioTelemetry's short interest can also be evaluated against the total number of BioTelemetry shares, or, against the total number of tradable BioTelemetry shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioTelemetry's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 BioTelemetry shares in existence, roughly 100 shares are currently held short) or 0.165% of the tradable shares (for every 100,000 tradable BioTelemetry shares, roughly 165 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BioTelemetry.

Find out more about how you can short BioTelemetry stock.

BioTelemetry share dividends

We're not expecting BioTelemetry to pay a dividend over the next 12 months.

BioTelemetry share price volatility

Over the last 12 months, BioTelemetry's shares have ranged in value from as little as $27.35 up to $56. A popular way to gauge a stock's volatility is its "beta".

BEAT.US volatility(beta: 1.19)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioTelemetry's is 1.186. This would suggest that BioTelemetry's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

BioTelemetry overview

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site